Jan. 29 Financial Quick Takes: Black Diamond prices upsized IPO; plus Biohaven, Denali, Concert follow-ons, Lyra, Annovis, Histogen-Conatus and CellFE

Black Diamond raises $201M in public debut
Black Diamond Therapeutics Inc. (NASDAQ:BDTX) raised $201.1 million late Wednesday through the sale of 10.6 million shares at $19 in a bumped-up IPO, valuing the company at $652.1 million. Black Diamond, which founding investor Versant Ventures launched in 2014 to develop tumor-agnostic small molecule therapies, had initially proposed to sell 8.9 million shares at $16-$18. The precision cancer company raised $194 million in venture rounds since its debut; Versant holds a 31% post-IPO stake, with NEA holding 8% and RA Capital 5% (see “NEA, RA Capital lead $85M B round for Black Diamond”).
Trio of biotechs price follow-ons
With its $250 million offering, Biohaven Pharmaceutical Holding Co. Ltd. (NASDAQ:BHVN) raised the largest amount among three biotechs that priced follow-ons this week. Biohaven sold 4.8 million shares at $51.75, an 8% discount to its close before it proposed the offering late Tuesday. The company expects a decision from FDA this quarter on Zydis rimegepant, which the agency is reviewing to treat migraine.

Also pricing offerings were neurodegeneration company Denali Therapeutics Inc. (NASDAQ:DNLI), which raised $180 million through the sale of 7.8 million shares at $23; and deuterium chemistry company Concert Pharmaceuticals Inc. (NASDAQ:CNCE), which raised $65 million by selling stock and warrants at $9.92...